A Triple-Blind, Placebo-Controlled, Randomized Clinical Trial of CANnabinoids for Drug Resistant Epilepsy in Adults and Children
Summary
This study is for children aged between 2 and 17 years who have Drug Resistant Epilepsy (DRE) to take part in a clinical research study. The primary purpose is to investigate if cannabinoids (CBD) work to reduce seizures in children with DRE, and if CBD works better alone or in combination with other cannabinoids including THC.
Eligibility
Eligible ages: 2 to 55
Inclusion criteria:
You or your child may be eligible to participate in this trial if you or your child:
1. Is 2 to 17 years of age, inclusive
2. Diagnosed with Drug Resistant Epilepsy: not achieved seizure freedom, with adequate trials of 2 antiseizure medications
Doctors will also evaluate other criteria to make sure you and your child qualify for the study.
Exclusion criteria:
You or your child may not be eligible to participate in this trial if you or your child:
- Has a diagnosis of psychogenic non-epileptic seizure
- Has recent (<30 days) change in anticonvulsant therapies
- Started ketogenic diet within 6 months
- Has vagal nerve stimulator implanted and activated within 12 months
- Has a clinically significant unstable medical condition
- Currently enrolled in a clinical study
Participate
Additional information
Contact information
Please contact Dr. Julia Jacobs-LeVan at Julia.Jacobs-LeVan@albertahealthservices.ca or study coordinator Ransi Nayakarathna at ransi.nayakarathna@albertahealthservices.ca
Principal investigator:
Julia Jacobs-Levan
Clinical trial:
Yes
REB-ID:
REB24-1245